Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 6/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | HTR2B | P41595 | 4/20 | 0.41 |
| ▸ | PRKCI | P41743 | 2/20 | 0.40 |
| ▸ | IKBKB | O14920 | 2/20 | 0.39 |
| ▸ | CHUK | O15111 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4009292 | 1.00 | ROCK1 (0.57) | ROCK1ROCK2KCNH2MAP2K1PRKCZ | |
| SCHEMBL4009293 | 1.00 | ROCK1 (0.57) | ROCK1ROCK2KCNH2MAP2K1PRKCZ | |
| SCHEMBL4009294 | 0.93 | ROCK1 (0.67) | ROCK1ROCK2KCNH2IRAK4IKBKB | |
| SCHEMBL4007136 | 0.93 | ROCK1 (0.64) | ROCK1ROCK2KCNH2PRKCZIKBKB | |
| SCHEMBL1205041 | 0.81 | ROCK1 (0.46) | ROCK1ROCK2KCNH2IRAK4 | |
| SCHEMBL12879225 | 0.81 | ROCK1 (0.46) | ROCK1ROCK2KCNH2IRAK4 | |
| SCHEMBL1205040 | 0.81 | ROCK1 (0.46) | ROCK1ROCK2KCNH2IRAK4 | |
| SCHEMBL1205636 | 0.81 | ROCK1 (0.46) | ROCK1ROCK2KCNH2IRAK4 | |
| SCHEMBL4010045 | 0.80 | ROCK1 (0.45) | ROCK1ROCK2KCNH2IKBKB | |
| SCHEMBL4007534 | 0.79 | ROCK1 (0.86) | ROCK1ROCK2KCNH2PRKCZIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963304-B2 | ISOQUINOLINE DERIVATIVES | MSD OSS BV (NL) | 2015-05-13 | — | — | EP | disclosed |
| US-7618985-B2 | Isoquinoline derivatives | N.V. ORGANON (NL) | 2009-11-17 | — | — | US | disclosed |
| EP-1963304-B1 | ISOQUINOLINE DERIVATIVES | ORGANON NV (NL) | 2009-06-24 | — | — | EP | disclosed |
| US-20070135479-A1 | Isoquinoline derivatives | N.V. ORGANON (NL) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135479-A1 | Isoquinoline derivatives | ROCK1, ROCK2, RHOA | ROCK1 1/4885ROCK2 2/4885KCNH2 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.